<table border="0" cellpadding="0" cellspacing="0" width="97%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<colgroup>
<col width="16.22%"></col>
<col width="83.78%"></col>
</colgroup>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Drugs   That   Interfere  with   Hemostasis</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics"> Clinical</content>
<content stylecode="italics">  </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">·    Naproxen   and   anticoagulants   such  as   warfarin   have  a   synergistic   effect   on   bleeding.  The   concomitant  use  of  naproxen  and  anticoagulants have   an   increased risk  of  serious   bleeding  compared   to   the  use  of   either  drug   alone.<br/>·     Serotonin   release by  platelets   plays  an important  role  in   hemostasis.  Case-control  and  cohort   epidemiological  studies   showed  that   concomitant  use  of  drugs   that   interfere   with   serotonin   reuptake  and  an   NSAID  may   potentiate  the  risk   of bleeding   more  than  an   NSAID   alone. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> Monitor   patients   with   concomitant  use  of  naproxen sodium  with   anticoagulants   (e.g.,   warfarin),   antiplatelet  agents   (e.g.,   aspirin),   selective  serotonin   reuptake   inhibitors  (SSRIs),   and   serotonin   norepinephrine   reuptake   inhibitors   (SNRIs)   for   signs   of  <content stylecode="italics"> bleeding  [see  <linkhtml href="#Section_5.12">Warnings  and  Precautions   (5.11)</linkhtml> ].</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold"> Aspirin</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics"> Clinical</content>
<content stylecode="italics">  </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top"> Controlled   clinical   studies   showed  that  the   concomitant  use  of  NSAIDs   and   analgesic  doses  of  aspirin does  not  produce   any greater therapeutic effect   than the  use   of  NSAIDs   alone.  In  a   clinical   study,  the   concomitant  use  of  an  NSAID   and   aspirin   was   associated   with  a   significantly   increased   incidence  of  GI  adverse   reactions   as  compared   to  use  of   the   NSAID  alone  <content stylecode="italics"> [see <content stylecode="underline">
<linkhtml href="#Section_5.2">Warnings and Precautions ( 5.2 )</linkhtml>
</content>].</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of naproxen sodium and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [<content stylecode="italics">see</content>
<content stylecode="italics"> <content stylecode="underline">
<linkhtml href="#Section_5.12">Warnings and Precautions (5.11)</linkhtml>
</content>
</content>]<content stylecode="italics">.</content>
<br/>Naproxen sodium is not substitutes for low dose aspirin for cardiovascular protection.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">·    NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).<br/>·    In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment,co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">·    During concomitant use of naproxen sodium and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.<br/>·    During concomitant use of naproxen sodium and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_5.7">Warnings and Precautions ( 5.6 )</linkhtml>
</content>].</content>
<br/>·    When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Diuretics</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of naproxen sodium with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [<content stylecode="italics">see</content>
<content stylecode="italics"> <content stylecode="underline">
<linkhtml href="#Section_5.7">Warnings and Precautions ( 5.6 )</linkhtml>
</content>
</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Digoxin</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of naproxen sodium and digoxin, monitor serum digoxin levels.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Lithium</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance<content stylecode="italics">.</content>
<content stylecode="italics"> </content>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of naproxen sodium and lithium, monitor patients for signs of lithium toxicity.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Methotrexate</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of naproxen sodium and methotrexate, monitor patients for methotrexate toxicity.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Cyclosporine</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of naproxen sodium and cyclosporine may increase cyclosporine’s nephrotoxicity. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of naproxen sodium and cyclosporine, monitor patients for signs of worsening renal function. <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">NSAIDs and Salicylates</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of naproxen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content stylecode="italics">[see <content stylecode="underline">
<linkhtml href="#Section_5.2">Warnings and Precautions ( 5.2 )</linkhtml>
</content>].</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">The concomitant   use   of   naproxen   with   other   NSAIDs   or   salicylates   is   not recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Pemetrexed</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant use of naproxen sodium and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">During concomitant use of naproxen sodium and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.<br/> <br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.<br/> <br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Antacids</content>
<content stylecode="bold"> </content>
<content stylecode="bold">and Sucralfate</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant administration of  some  antacids (magnesium  oxide  or  aluminum hydroxide) and sucralfate can delay the absorption of naproxen.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant administration of antacids such as magnesium oxide or aluminum hydroxide, and sucralfate with naproxen sodium is not recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Cholestyramine</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant administration of cholestyramine can delay the absorption of naproxen.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Concomitant administration   of  cholestyramine   with naproxen sodium is not recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Probenecid</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Patients simultaneously   receiving   naproxen sodium and probenecid should be observed for adjustment of dose if required.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule" valign="middle">
<content stylecode="bold">Other albumin-bound drugs</content> <br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Clinical</content>
<content stylecode="italics"> </content>
<content stylecode="italics">Impact:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Naproxen is highly bound to plasma albumin; it thus has a theoretical potential for interaction with other albumin-bound drugs such as coumarin-type anticoagulants, sulphonylureas, hydantoins, other NSAIDs, and aspirin<content stylecode="italics">.</content>
<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content> <br/>
</td>
<td align="justify" stylecode="Rrule" valign="top">Patients simultaneously receiving naproxen sodium and a hydantoin, sulphonamide or sulphonylurea should be observed for adjustment of dose if required.<br/>
</td>
</tr>
</tbody>
</table>